Instil Bio, Inc. TIL

About Instil Bio, Inc. (TIL): stock profile, AI score and financials

Instil Bio, Inc. (TIL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TIL at 16.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,798 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (2.4) and profitability (4.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Instil Bio, Inc. reports quarterly revenue of $2.2M, net income of $-4.3M. Top institutional holders of TIL by reported 13-F value include Curative Ventures V, BML Capital Management, Vivo Capital, based on the most recent SEC filings. TIL trades on the Nasdaq exchange and files with the SEC under CIK 1789769. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TIL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Instil Bio, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1789769 →